Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2- metastatic breast cancer in Japan.

Naito Y, Aruga T, Tanizawa Y, Terasawa T, Kawaguchi T, Takano T

Open source

DOI
10.1080/14796694.2026.2727324
Published
2026 Sep 11
Container
Future oncology (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2727324,
  title = {Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2- metastatic breast cancer in Japan.},
  author = {Naito Y and Aruga T and Tanizawa Y and Terasawa T and Kawaguchi T and Takano T},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2727324},
  url = {https://doi.org/10.1080/14796694.2026.2727324}
}

RIS

TY  - JOUR
TI  - Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2- metastatic breast cancer in Japan.
AU  - Naito Y
AU  - Aruga T
AU  - Tanizawa Y
AU  - Terasawa T
AU  - Kawaguchi T
AU  - Takano T
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2727324
UR  - https://doi.org/10.1080/14796694.2026.2727324
ER  - 

APA

Y, N., T, A., Y, T., T, T., T, K., & T, T. (2026). Treatment patterns after first-line abemaciclib therapy in patients with HR+, HER2- metastatic breast cancer in Japan.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2727324

Source records